Baseline history of patients using selexipag for pulmonary arterial hypertension
Introduction: Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-naïve patients and those with mono or dual therapy failure; however, limited information is available regarding the presentation and management of patients with pulmonary a...
| Үндсэн зохиолчид: | , , , , , |
|---|---|
| Формат: | Өгүүллэг |
| Хэл сонгох: | English |
| Хэвлэсэн: |
SAGE Publishing
2019-04-01
|
| Цуврал: | Therapeutic Advances in Respiratory Disease |
| Онлайн хандалт: | https://doi.org/10.1177/1753466619843774 |